LifeStance Health Group reports developments as a Nasdaq-listed provider of virtual and in-person outpatient mental healthcare. The company serves children, adolescents and adults through psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy.
Recurring news themes include quarterly operating results, visit volumes, clinician productivity, center-level margin trends, cash flow, debt and capital allocation. Company updates also cover secondary common stock offerings by selling stockholders, share repurchase activity, investor conference presentations, executive and board changes, and corporate-status announcements tied to its outpatient mental health services business.
LifeStance Health (LFST) released a survey finding that fear of becoming social media content limits public self-expression for 47% of respondents.
Among Gen Z respondents, concerns about being recorded and shared online affect enjoyment of the present moment for 74% and the desire to leave home or attend events for 72%, compared with 52% and 48% across all respondents. Gen Z respondents also reported weekly negative effects on mood (47%), confidence and self-esteem (44%), sleep (43%) and anxiety (42%). Across generations, 20% have avoided social gatherings with friends and 19% have avoided bars or nightlife.
One in five respondents believe therapy can help address this social anxiety; 19% would consider therapy if these concerns began affecting daily life. Dynata conducted the survey for LifeStance in July 2026, collecting responses from 1,000 U.S. adults ages 18 and up.
LifeStance Health Group (LFST) priced a secondary public offering of 22,250,000 common shares at $12.35 per share.
All proceeds will go to selling stockholders; the company is not issuing shares and will receive no proceeds. LifeStance agreed to repurchase 2,000,000 shares from the underwriter, conditional on the offering’s completion, with both transactions expected to close on or about September 11, 2026. Barclays is acting as sole underwriter.
LifeStance Health Group (LFST)/b) announced that certain existing stockholders plan to sell 22,250,000 shares of its common stock in a secondary offering under an effective shelf registration statement.The selling stockholders will receive all proceeds and the company will not sell any shares or receive any proceeds. LifeStance has also authorized a concurrent repurchase of 2,000,000 shares from the underwriter at the same per-share price paid to the selling stockholders, subject to completion of the offering and customary conditions. Barclays is acting as the sole underwriter, and the offering will be made only by means of a prospectus and related prospectus supplement filed with the SEC.
LifeStance Health Group (NASDAQ: LFST) announced that its management will present at two investor conferences in September 2026. The CFO, Ryan McGroarty, will present at the 2026 Jefferies Healthcare Services and Technology Conference in Nashville on September 14, while CEO Dave Bourdon will speak at the 24th Annual Morgan Stanley Healthcare Conference in New York on September 15.
Both presentations will be webcast live, with live and replay access available through the Events and Presentations section of the LifeStance Health investor relations website.
LifeStance Health (LFST) released results from a survey of 1,000 women born between 1960-1990 who are experiencing or suspect perimenopause or menopause. The survey highlights that 33% did not know perimenopause can cause mental health symptoms, while many report severe anxiety (66%) and depression (54%).
According to LifeStance, 83% of respondents who tried therapy and 82% who tried prescribed medications such as antidepressants or estrogen found them helpful. Nearly half (47%) believe mental healthcare should be standard in perimenopause care, and 59% would be more likely to seek it if they knew it could significantly improve symptoms.
LifeStance Health (Nasdaq: LFST) reported Q2 2026 revenue of $435.4 million, up 26% year over year, with visit volumes up 19% to 2.6 million and its clinician base up 11% to 8,542. Net income turned positive to $23.6 million from a $3.8 million loss, and Adjusted EBITDA rose to $66.0 million (15.2% margin) from $34.0 million.
Center Margin increased 41% to $153.0 million (35.2% of revenue). According to LifeStance, operating cash flow was $99.9 million in Q2 and $133.0 million year-to-date, with free cash flow of $87.9 million in Q2. The company raised full-year 2026 guidance to revenue of $1.685–$1.725 billion, Center Margin of $570–$594 million, and Adjusted EBITDA of $215–$235 million, and announced a new $100 million share repurchase program replacing its prior authorization.
LifeStance (NASDAQ: LFST), a large U.S. outpatient mental healthcare provider, will release its second quarter 2026 earnings before the market opens on Thursday, August 6, 2026. On the same day, the company will host a live earnings conference call at 8:30 a.m. Eastern Time to discuss its quarterly results.
Investors can join the call by dialing 1-800-715-9871 domestically or 1-646-307-1963 internationally and using conference ID 6776851, or by asking to be joined into the LifeStance call. A real-time audio webcast and related materials will be available in the Events and Presentations section of the LifeStance Investor Relations website, with a webcast replay accessible after the call concludes.
LifeStance Health Group (Nasdaq: LFST) priced a secondary offering of 35,000,000 common shares at $8.15 per share on May 7, 2026. The Selling Stockholders will receive all proceeds; LifeStance is not selling shares and will not receive offering proceeds.
The company agreed to a conditional Repurchase of 6,000,000 shares from the selling holders at the same price; the Repurchase is conditioned on closing and customary conditions. Settlement is expected on or about May 12, 2026, with J.P. Morgan as underwriter.
LifeStance Health Group (Nasdaq: LFST) announced that certain selling stockholders intend to offer 35,000,000 shares of common stock in a secondary offering on May 7, 2026. The Company will not sell shares or receive proceeds from that offering.
LifeStance authorized a concurrent repurchase of 6,000,000 shares from the underwriter, at the same per-share price paid by the underwriter to the selling stockholders; the underwriter will not receive underwriting fees on repurchased shares. J.P. Morgan is the underwriter. The offering relies on a shelf registration that became effective May 21, 2024.
LifeStance Health (Nasdaq: LFST) reported Q1 2026 results: revenue $403.5M (+21% YoY), clinicians 8,349 (+11%), visits 2.5M (+18%), net income $14.2M, and Adjusted EBITDA $51.1M (+48%).
Cash from operations was $33.1M, free cash flow $22.3M, ending cash $194.8M and net long-term debt $262.5M. Full-year 2026 guidance raised to $1.64B–$1.68B revenue and $200M–$220M Adjusted EBITDA.